Peptide COA Review Example: What to Check

A peptide COA review example is useful only when it shows the information required to assess a specific lot, not when it presents a generic purity claim. For research-grade peptides, the Certificate of Analysis should connect the material in hand to defined analytical methods, measurable results and a traceable batch record.

A COA is not marketing collateral. It is a controlled quality document that helps a laboratory or scientific purchaser determine whether a peptide is appropriately characterised for its intended non-clinical research application. The document should be reviewed alongside product handling requirements, storage conditions and, where applicable, supporting chromatographic data.

What a peptide COA should establish

At minimum, a credible peptide COA establishes four points: the material's identity, its measured purity, its lot-specific traceability and the test methods used to obtain the reported results. Missing any one of these points weakens the document's value.

Identity confirms that the supplied material corresponds to the stated peptide. Purity indicates the proportion of the tested sample attributed to the target peak under the stated analytical method. Traceability ties the results to a particular batch or lot. Method information provides the context needed to interpret the result rather than treating a percentage in isolation.

For example, an HPLC purity result of 99%+ is meaningful only if the COA identifies the lot tested, the method used and the acceptance specification. It does not, by itself, establish peptide identity, peptide content, sterility or suitability for human use. Research-grade peptide materials must remain designated for research use only.

Peptide COA review example

The following illustrative format shows the type of information a reviewer should expect. It is an example only, not a product certificate or a substitute for lot-specific documentation.

| COA field | Example entry | Why it matters |
|---|---|---|
| Product name | Peptide X, lyophilised powder | Matches the ordered material and physical form |
| Catalogue reference | PB-RP-XXX | Supports internal procurement records |
| Lot number | PX240601-A | Links the vial, COA and analytical results |
| Manufacturing date | 01 June 2024 | Establishes the batch timeline |
| Retest date | 01 June 2026 | Indicates the period covered by the quality review when stored as specified |
| Peptide sequence | Stated amino acid sequence | Provides the intended molecular identity |
| Molecular mass | Calculated and observed mass | Supports identity confirmation by mass spectrometry |
| Identity method | LC-MS or MALDI-TOF MS | States how identity was assessed |
| Purity method | RP-HPLC, UV detection | States the chromatographic basis of the purity result |
| Purity result | 99.2% | Must be read against the stated method and specification |
| Appearance | White to off-white lyophilised powder | A basic physical-description check |
| Storage | Store as specified, protected from moisture | Supports material stability during laboratory storage |
| Authorisation | Quality review signature or controlled release reference | Shows formal document control |

A strong certificate will also identify the issue date, document version and testing laboratory or quality function. If third-party testing has been used, the relationship between the external report and the supplier lot should be clear. A report that cannot be tied to the supplied lot is not equivalent to batch-specific verification.

Start with lot matching

The lot number is the first item to verify. It should be legible on the vial label or secondary packaging and match the lot number on the COA exactly. A catalogue number identifies a product type; it does not identify the individual material tested. For procurement records, retain the COA with the associated receipt, storage log and any relevant delivery-condition record.

A common weakness is a document labelled as a COA that lists only a product name and a broad purity statement. Without a lot number, there is no reliable basis for confirming that the analysed sample is the material received.

Confirm identity beyond the product label

For synthetic peptides, mass spectrometry is commonly used to support identity confirmation. The COA should ideally state the calculated molecular mass and the observed mass, with a method such as LC-MS or MALDI-TOF MS. Agreement between expected and observed mass supports the expected molecular composition, although it should be interpreted in the context of the analytical method and peptide chemistry.

Identity can become more complex where salts, counterions, modifications or conjugates are involved. A peptide supplied as an acetate, trifluoroacetate or other salt may have reporting conventions that differ from the neutral peptide mass. The certificate should make the material form sufficiently clear for the laboratory to interpret the result correctly.

How to interpret HPLC purity correctly

Reverse-phase HPLC is a standard method for evaluating peptide purity. The reported percentage is normally based on the relative area of the target chromatographic peak. A 99%+ HPLC result indicates a high proportion of the detected chromatographic signal is assigned to the principal peak under that specific method.

It does not automatically mean 99% peptide content by weight. Residual water, counterions, salts and volatile components can affect net peptide content without necessarily appearing as major chromatographic impurities. This distinction matters when a protocol requires accurate material characterisation rather than a headline purity figure.

A useful COA identifies the chromatographic conditions at an appropriate level, such as column type, mobile phases, detection wavelength and retention time. More detailed supporting data, including the chromatogram, may be particularly valuable for method development, comparative lot assessment or investigations of unexpected research results.

Review the stated acceptance criterion as well. A result of 99.2% is stronger when presented against a defined release specification, such as not less than 99.0% by RP-HPLC, than when it is displayed without a specification. The method, specification and result should form a coherent set.

Look for results that are specific, not vague

Terms such as “tested”, “premium quality” or “pharmaceutical-grade” are not analytical results. Quality language should be supported by measurable, lot-specific data. At a minimum, reviewers should be able to locate the test result, unit of measure, acceptance criterion where relevant, analytical method and batch identifier.

The appropriate testing package depends on the peptide and the planned research workflow. A short, unmodified peptide may require a different level of supporting information from a modified, highly hydrophobic or conjugated compound. It depends on the material risk profile, experimental sensitivity and the controls already established in the laboratory.

Check handling and documentation together

A technically sound COA cannot correct poor handling after release. Review stated storage conditions before receipt and ensure the material is protected from avoidable temperature and moisture exposure. For temperature-sensitive research materials, shipment method and delivery timing form part of the practical quality chain.

On receipt, inspect packaging condition, confirm the label and lot number, and move the peptide to the specified storage environment without unnecessary delay. Record any discrepancy before the material enters a research workflow. A damaged label, missing lot reference or unexplained temperature concern should be resolved through the supplier's quality process.

At Peptide Biosciences, COA verification, HPLC testing and controlled fulfilment are presented as connected quality controls rather than isolated claims. That approach reflects a practical laboratory requirement: documentation is most useful when it remains traceable from product selection through delivery and storage.

Questions to ask when a COA is incomplete

If the certificate does not provide enough information for a purchasing decision, request clarification before using the material. Ask whether the document is lot-specific, whether identity was confirmed by mass spectrometry, which method generated the purity result and whether a chromatogram or third-party report is available where required.

Also ask about the reported material form. Counterion identity, water content and net peptide content may be relevant to analytical planning, even when the HPLC purity meets specification. These are not interchangeable measurements, and treating them as such can introduce avoidable variability.

A COA should make a laboratory more confident in its records, not force it to infer missing facts. When the lot number, identity result, HPLC method, purity outcome and handling requirements align, the document becomes a useful part of disciplined research control. Keep that standard at the point of purchase, because the easiest quality issue to resolve is the one identified before a vial enters the study.